Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone33-1-81-69-16-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.43 million
Profitability
Miscellaneous
Employees161
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
Cellectis (NASDAQ:CLLS) Frequently Asked Questions
What is Cellectis' stock symbol?
Cellectis trades on the NASDAQ under the ticker symbol "CLLS."
How were Cellectis' earnings last quarter?
Cellectis SA (NASDAQ:CLLS) issued its quarterly earnings results on Monday, March, 11th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.14. The biotechnology company earned $3.08 million during the quarter, compared to analyst estimates of $7.46 million. Cellectis had a negative return on equity of 14.85% and a negative net margin of 401.24%. View Cellectis' Earnings History.
When is Cellectis' next earnings date?
What price target have analysts set for CLLS?
5 Wall Street analysts have issued 1 year target prices for Cellectis' shares. Their predictions range from $22.00 to $50.00. On average, they expect Cellectis' share price to reach $35.25 in the next year. This suggests a possible upside of 92.7% from the stock's current price. View Analyst Price Targets for Cellectis.
What is the consensus analysts' recommendation for Cellectis?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.
Has Cellectis been receiving favorable news coverage?
Media stories about CLLS stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cellectis earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Are investors shorting Cellectis?
Cellectis saw a decrease in short interest during the month of April. As of April 15th, there was short interest totalling 303,560 shares, a decrease of 39.4% from the March 29th total of 500,687 shares. Based on an average daily trading volume, of 110,338 shares, the days-to-cover ratio is presently 2.8 days. Approximately 0.7% of the shares of the stock are sold short. View Cellectis' Current Options Chain.
Who are some of Cellectis' key competitors?
Some companies that are related to Cellectis include Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Orchard Therapeutics (ORTX), Alector (ALEC), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Fate Therapeutics (FATE) and Sangamo Therapeutics (SGMO).
What other stocks do shareholders of Cellectis own?
Who are Cellectis' key executives?
Cellectis' management team includes the folowing people:
- Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
- Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
- Mr. Eric Dutang, Chief Financial Officer (Age 45)
- Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
- Mr. Jean Charles Epinat, Chief Technological Officer
When did Cellectis IPO?
(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.
Who are Cellectis' major shareholders?
Cellectis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (10.14%), ARK Investment Management LLC (2.25%), Nikko Asset Management Americas Inc. (1.98%), Sumitomo Mitsui Trust Holdings Inc. (1.96%), BlackRock Inc. (1.16%) and Morgan Stanley (0.76%).
Which major investors are selling Cellectis stock?
CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Henry James International Management Inc., WS Management Lllp and BlackRock Inc..
Which major investors are buying Cellectis stock?
CLLS stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, Lazard Asset Management LLC, Morgens Waterfall Vintiadis & Co. Inc., JPMorgan Chase & Co., Envestnet Asset Management Inc. and Wells Fargo & Company MN.
How do I buy shares of Cellectis?
Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectis' stock price today?
One share of CLLS stock can currently be purchased for approximately $18.29.
How big of a company is Cellectis?
Cellectis has a market capitalization of $760.86 million and generates $21.43 million in revenue each year. The biotechnology company earns $-78,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Cellectis employs 161 workers across the globe.
What is Cellectis' official website?
How can I contact Cellectis?
Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]
MarketBeat Community Rating for Cellectis (NASDAQ CLLS)
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
